revenu declin due increas competit due patent expir
upgrad hold rate upgrad tp
tp base forward price-to-earnings multipl
adjust ep provid
upsid potenti
estim base follow factor declin
revenu core product enbrel growth newli
launch product declin net sell price
total revenu decreas
reflect increas competit due patent
expir compani expect revenu rang
continu reflect
rang evolv competit dynam associ
neulasta legaci product expect declin
revenu growth revenu
total product revenu decreas
decreas decreas
due declin net sell price unfavour
chang inventori off-set partial higher unit demand
earn per share ep increas
quarter benefit lower weighted-averag share
outstand non-gaap ep increas
benefit lower weighted-averag share outstand
total revenu prolia increas
due higher unit demand total revenu
kyproli increas driven
higher unit demand unit state
compani name inc tickeramgnstock ratingholdupgradeindustri viewoverweightpositivepric oct week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth inc octob
incom statement
non-
per share item
product perform develop
valuat consensu perform
total revenu sensipar/mimpara decreas
increas driven primarili
impact at-risk launch gener competitor
total revenu enbrel increas
increas driven increas net sell
price favor chang inventori off-set partial
total revenu neulasta decreas
decreas due lower net
sell price impact biosimilar competit
unit demand total sale includ order
 govern
august announc enter
agreement celgen corpor connect
previous announc merger bristol-my
squibb compani acquir world-wide right otezla
oral non-biolog treatment psoriasi psoriat
arthristi certain relat asset liabil
cash net present valu
anticip futur cash tax benefit
price-to-earnings trail
current price-to-earnings
averag price-to-earnings expect forward price-to-earnings
compani gener free
cash flow compar
driven advanc tax deposit payment
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date sep ex-dividend date aug last split factor new per last split date inform amgen inc octob
incom statement
non-
per share item
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement item total gross research sale gener oper total oper oper interest incom incom provis incom net incom avail common weight averag share annual actual annual actual quarterli inc octob
equival short term invest total st invest receiv account receiv total receiv current asset inventori current asset total current asset long-term asset gross properti plant equip accumul depreci net properti plant equip long-term invest goodwil intang long-term asset total asset current liabil account payabl accru expens short-term borrow current portion lt debt current liabil total current liabil long-term liabil long-term debt def tax liabil non-curr non-curr liabil total liabil common equiti common stock retain earn comprehens incom total common equiti stockhold equiti total equiti liabil equiti total liabil equiti balanc sheet itemsactu annual actual quarterli inc octob
flow oper activ decreas compar
due increas payment ir relat advanc deposit increas sale
deduct paid custom lower net incom
provid invest activ compar
decreas due net cash inflow relat market secur
use financ activ compar due
repurchas common stock repay debt payment dividend
incom oper activitiesdepreci amort amort goodwil intang depreci amort total asset write-down restruc cost stock-bas compens oper activ chang account receiv chang inventori account payabl incom tax net oper asset oper invest activitiescapit expenditur properti plant equip acquisit sale purchas intang asset invest market equiti securt invest activ invest financ activitiesshort term debt issu long-term debt issu total debt issu short term debt repaid long-term debt repaid total debt repaid common stock repurchas common stock prefer stock dividend paid financ activ financ equivalentsnet chang inc octob
report declin revenu strong volum
driven growth new recent launch product
total revenu decreas compar
reflect increas competit due patent
expir total product revenu decreas
compar decreas due declin net
sell price off-set partial higher unit demand
total revenu decreas compar
due lower mileston payment off-set partial
gaap sale decreas compar
gaap sale product revenu
compar gaap sale total
revenu compar
decreas due unfavour product mix off-set partial benefit
hurrican maria insur proce lower manufactur cost
decreas
compar
increas
compar
non-gaap sale compar
non-gaap cog product sale increas
compar
 expens increas compar
 expens product revenu
compar
non-gaap expens increas
compar non-gaap expens
product sale compar
sg expens decreas compar
sg expens product revenu
decreas compar
increas due lower discretionari gener administr expens
end certain amort intang asset
non-gaap sg expens decreas
compar non-gaap sg expens
product sale decreas compar
decreas
compar
oper expens decreas compar
oper expens decreas
compar non-gaap oper expens
decreas compar
decreas
compar
oper incom decreas
compar non-gaap oper incom decreas
compar
oper incom product sale decreas
compar non-gaap oper incom
product sale compar
net interest expens decreas compar
net interest incom increas
compar
gaap incom incom tax decreas
compar non-gaap incom incom tax
decreas compar
tax rate compar non-
tax rate increas compar
gaap net incom decreas compar
non-gaap net incom decreas
compar ep
compar non-gaap ep increas
compar
total revenu decreas compar
total product revenu decreas
compar decreas due
declin net sell price unfavour chang inventori off-set
partial higher unit demand total revenu decreas
compar
gaap sale increas compar
gaap sale product revenu
compar gaap sale total
revenu compar
decreas due unfavour product mix higher manufactur cost
off-set partial benefit hurrican maria insur proce
non-gaap sale increas compar
non-gaap cog product sale increas
compar
 expens increas compar
 expens product revenu
compar increas driven
increas spend research earli pipelin support amgen
oncolog program off-set partial decreas spend support
non-gaap expens increas
compar non-gaap expens product
sale compar
sg expens decreas compar
sg expens product revenu
decreas compar
increas due end certain amort intang asset
lower discretionari gener administr expens off-set partial
invest launch product
decreas
compar
increas
compar
non-gaap sg expens decreas
compar non-gaap sg expens
product sale remain flat compar
oper expens decreas compar
decreas due legal proceed
oper expens increas compar
non-gaap oper expens increas
compar
oper incom decreas
compar non-gaap oper incom decreas
compar
oper incom product sale decreas
compar non-gaap oper incom
product sale compar
net interest expens decreas compar
decreas due reduct outstand
long-term debt result matur off-set partial rise
interest rate variable-r debt
net interest incom increas
compar increas due tax benefit
associ inter-company sale corpor tax reform
gaap incom incom tax decreas
compar non-gaap incom incom tax
decreas compar
tax rate compar non-
tax rate increas compar
increas
compar
gaap incom
compar
gaap net incom decreas compar
non-gaap net incom decreas
compar ep
compar non-gaap ep increas
compar
market six therapeut area cardiovascular neurosci
oncology/hematolog inflamm nephrolog bone health
princip product neulasta enbrel sensipar/mimpara prolia
aranesp xgeva epogen also market number product
parsabiv imlyg corlanor aimovig kanjinti
total product sale decreas compar
total product sale decreas
compar
total product sale decreas
compar total product sale
decreas compar
total product sale rest world increas
compar increas
compar
total revenu prolia increas
compar increas
compar increas due
total revenu increas
compar increas
compar
decreas
compar
total revenu prolia
increas
increas
total revenu rest world increas
compar increas
compar
total revenu xgeva increas
compar increas
compar increas due
total revenu increas
compar increas
compar
total revenu rest world increas
compar increas
compar
total revenu kyproli increas
compar increas
compar increas primarili
driven higher unit demand unit state
total revenu increas
compar increas
compar total revenu rest
world decreas compar
decreas
compar
total revenu xgeva
increas
increas
total revenu
kyproli increas
increas
total revenu parsabiv compar
compar
total revenu compar
compar
total revenu rest world
compar compar
total revenu repatha increas
compar increas
compar
total revenu decreas
compar decreas
compar total revenu rest
world increas compar
increas compar
total revenu sensipar/mimpara decreas
compar decreas
compar increas
driven primarili impact at-risk launch gener
total revenu decreas
compar decreas
compar total revenu
rest world decreas compar
decreas
compar
total revenu
repatha increas
increas
total revenu
decreas
decreas
total revenu nplate increas
compar increas
compar
total revenu nplate
increas
increas
total revenu increas
compar increas
compar total revenu rest
world increas compar
increas compar
total revenu
blyncyto increas
increas
total revenu blyncyto increas
compar increas
compar
total revenu increas
compar increas
compar total revenu rest
world increas compar
increas compar
total revenu vectibix increas
compar increas
compar
total revenu increas
compar increas
compar total revenu rest
world increas compar
increas
compar
total revenu aranesp decreas
compar decreas
compar declin due
impact competit unit demand unit state
total revenu
aranesp decreas
decreas
total revenu decreas
compar decreas
compar total revenu rest
world compar
total revenu enbrel
increas
compar
total revenu epogen decreas
compar decreas
compar decreas epogen
sale due decreas net sell price due contractu term
negoti davita inc
total revenu enbrel increas
compar increas driven increas
net sell price favor chang inventori off-set partial
total revenu increas compar
due favor impact chang account
estim sale deduct product return increas net
sell price partial off-set unfavor chang inventori lower
total revenu increas
compar increas
compar total revenu canada
decreas compar
decreas compar
total revenu aimovig compar
compar
total revenu decreas
compar decreas
compar
total revenu decreas
compar decreas
compar total revenu rest
world decreas compar
decreas
compar
total revenu neulasta decreas
compar decreas
compar decreas due
lower net sell price impact biosimilar competit unit
demand total sale includ order govern
total revenu decreas
compar decreas
compar total revenu rest
world decreas compar
decreas
compar
total revenu
decreas
decreas
total revenu
neulasta decreas
decreas
juli phase
follow signific develop
june intermountain healthcar decod genet wholly-own
subsidiari base iceland announc global collabor
combin intermountain internationally-recogn expertis
precis medicin clinic care decod world-class expertis
human popul genet involv particip
juli compani complet acquisit nuevolut
rapidli integr world-class dna-encod librari
juli phase galactic-hf cardiovascular outcom clinic trial
june committe medicin product human use chmp
european medicin agenc adopt neg opinion
market author applic even treatment
sever osteoporosi juli ucb submit written notic
european medicin agenc request re-examin chmp
compani discuss long-term efficaci safeti data recent
present meet american academi neurolog
american headach societi
result phase
studi abp
biosimilar candid
rituxan patient
lymphorma expect
compani provid clinic updat includ tumor respons
colorect appendic cancer patient complet enrol
dose expans arm enrol initi checkpoint
inhibitor combin arm first-in-human studi initi
potenti registr monotherapi studi plan year
result phase studi abp biosimilar candid
rituxan rituximab patient non-hodgkin lymphoma
expect
compani announc food drug
administr fda set dec biosimilar user fee act
target action date biolog licens applic abp
biosimilar candid remicad infliximab
acquir otezla
august announc enter
agreement celgen corpor connect previous
announc merger bristol-my squibb compani acquir
world-wide right otezla oral non-biolog treatment
psoriasi psoriat arthristi certain relat asset liabil
cash net present valu
otezla lead treatment post-typ pre-biolog segment
approv indic otezla current approv three indic
 treatment patient moderate-to-sever plaqu
psoriasi candid phototherapi system therapi adult
patient activ psoriat arthriti adult patient oral ulcer
associ behcet diseas
acquisit otezla
opportun
provid patient
psoriasi psoriat
arthriti fit squar
complement enbrel
amgevita brand
acquir otezla
otezla approv market outsid includ
european union japan patent exclus least
 sale otezla driven strong
acquisit otezla offer uniqu opportun
provid patient innov oral therapi psoriasi psoriat
arthriti fit squar within portfolio complement
enbrel amgevita brand
transact benefit near long-term growth rate
immedi accret close non-gaap
earn per share growth financ transact
current balanc sheet cash expect retain invest grade
enbrel otezla complementari enbrel frequent
prescrib treat moderate-to-sever rheumatoid arthriti otezla
posit therapi first-choic patient moderate-to-
sever psoriasi satisfi topic therapi given
differenti mechan action establish efficaci safeti
otezla posit use patient earli diseas and/or
moder joint involv addit studi current
underway explor potenti new indic otezla includ mild-
believ signific opportun grow otezla
global expans new indic expect otezla
realiz least low double-digit sale growth averag next
total revenu expect rang
basi ep rang tax rate
rang
non-gaap basi ep rang tax rate
rang
report declin revenu quarter due increas
competit patent expir total revenu decreas
compar decreas
compar
deploy repurchas million share
averag price per share compani plan purchas
increment share addit
dividend increas per share increas last year
injector replac two present coupl
expans retail believ small one-tim increas
amount product channel quarter prepar demand
cash invest total decreas
primarili due share repurchas debt repay
compani debt balanc stand june reduct
approxim year ago continu pay debt
basi ep
rang
tax rate
rang
growth revenu
due growth
non- reconcili
non- reconcili
non- reconcili
incom statement
non-
per share item
product perform develop
valuat consensu perform
revenu growth ttm basi compar
ep growth ttm basi compar
net margin ttm basi increas compar
oper margin ttm basi compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag marginsprofitabilityrevenu growth oper incom growthep growth inc octob
mrqgross mrqoper mrqnet mrqcog mrqsg mrqr sale amgen inc octob
mrqyoy growth revenu growthoper incom growthep mrqfinanci mrqreturn mrqreturn asset amgen inc octob
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net net margin annual itemsquarterli item amgen inc octob
outstand equival market debt common prefer stock- purchas properti plant sale properti plant purchas sale business- purchas sale issuanc repurchas net issuanc net chang capit free inc octob
price-to-earnings trail current price-to-earnings
averag price-to-earnings expect forward price-to-earnings
incom statement
non-
per share item
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdersharesd report outvaluevanguard group inc capit research global fmr primecap manag geod capit manag northern trust america top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard vanguard/primecap invest compani capit incom builder spdr etf vanguard institut fund-institut etf tr- qqq tr seri etf american mutual fund inc fidel competit
develop announc posit result phase blincyto blinatumomab studi pediatr patient replac acut lymphoblast leukemia septemb today announc result pre-specified interim analysi open-label random control global multicent phase trial show primari endpoint event-fre surviv met studi evalu efficaci safeti toler blincyto blinatumomab compar conventi consolid chemotherapi pediatr patient high-risk b-cell acut lymphoblast leukemia first relaps enrol termin earli due encourag efficaci blincyto arm base recommend independ data monitor committe dmc follow continu prescrib per protocol announc phase candor studi combin kyproli carfilzomib darzalex daratumumab meet primari endpoint progression-fre surviv septemb today announc phase candor studi evalu kyproli carfilzomib combin dexamethason darzalex daratumumab kdd compar kyproli dexamethason alon kd met primari endpoint progression-fre surviv regimen result reduct risk progress death patient relaps refactori multipl myeloma treat kdd median patient treat kd alon month median patient treat kdd reach cut-off date aqcuir otezla approxim net anticip futur tax benefit august announc today enter agreement celgen corpor connect previous announc merger bristol-my squibb compani acquir world-wide right otezla oral non-biolog treatment psoriasi psoriat arthriti certain relat asset liabilit cash approxim net present valu anticip futur cash tax benefit allergan mvasi bevacizumab-awwb kanjinti trastuzumab-ann avail unit statesjuli allergan plc today announc mvasi biosimilar avastin kaninti biosimilar herceptin avail unit state mvasi first oncolog therapeut biosimilar approv food drug administr fda approv treatment five type cancer combin chemotherapi metastat colorect cancer mcrc combin chemotherapi non-squam non-smal cell lung cancer nsclc recurr glioblastoma combin interferon-alfa metastat renal cell carcinoma combin chemotherapi persist recurr metastat cervic cancer inc octob
incom statement
non-
per share item
product perform develop
valuat consensu perform
compar
roa roi roe
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit inc octob
consensu view analyst trend stock
forecast
compar
forward price-to-earnings
compar
amgn avgfive-year growth forecast usdgrowth high day day day estim comparisonamgnindustri avg avgprice/earn yield inc octob
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr
next qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last daysn/an/an/an/adown last daysobsoleteobsoleteobsoleteobsoletedown last dayscurr growth ratescurr surprisescurr amgen inc octob
incom statement
non-
per share item
product perform develop
valuat consensu perform
stock price dip juli upward trend august
stock gave return period averag daili volum share trade
quarter
stock price show huge fluctuat year surg august
stock declin past one year rang stock
stock price show upward trend surg august
stock given return past due growth busi
revenu decreas due increas competit due patent
expir recommend hold rate tp base forward price-to-earnings multipl
adjust ep base uncertainti growth compani
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
